An EY (formerly Ernst & Young) survey around data integrity compliance issues within the Indian pharmaceutical sector has thrown up some potentially worrisome findings, including an absence of quality processes and procedures at some firms amid work pressure and manpower shortages.
An EY (formerly Ernst & Young) survey around data integrity compliance issues within the Indian pharmaceutical sector has thrown up some potentially worrisome findings, including an absence of quality processes and procedures at some firms amid work pressure and manpower shortages.
The survey, which covers more than 170 respondents from the pharmaceutical industry in India during January-March 2015, found that 33% of the respondents did not conduct reviews to assess potential...
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
